Should I buy or sell 23andMe stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 23andMe in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ME shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ME, but not buy additional shares or sell existing shares. View ME analyst ratings or view top-rated stocks .

What is 23andMe's stock price target for 2024?

1 brokerages have issued 12 month price objectives for 23andMe's shares. Their ME share price targets range from $0.47 to $0.47. On average, they expect the company's share price to reach $0.47 in the next year. This suggests that the stock has a possible downside of 11.8%. View analysts price targets for ME or view top-rated stocks among Wall Street analysts .

How have ME shares performed in 2024?

23andMe's stock was trading at $0.9135 on January 1st, 2024. Since then, ME shares have decreased by 41.7% and is now trading at $0.5329. View the best growth stocks for 2024 here .

When is 23andMe's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 23rd 2024. View our ME earnings forecast .

How were 23andMe's earnings last quarter?

23andMe Holding Co. (NASDAQ:ME) posted its quarterly earnings results on Wednesday, February, 7th. The company reported ($0.17) earnings per share (EPS) for the quarter. The business had revenue of $44.75 million for the quarter, compared to the consensus estimate of $56.30 million. 23andMe had a negative net margin of 210.48% and a negative trailing twelve-month return on equity of 52.99%.

What ETF holds 23andMe's stock?

Global X Telemedicine & Digital Health ETF holds 539,538 shares of ME stock, representing 0.81% of its portfolio.

What guidance has 23andMe issued on next quarter's earnings?

23andMe updated its FY 2024 earnings guidance on Wednesday, February, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $215.0 million-$220.0 million, compared to the consensus revenue estimate of $245.5 million.

Who are 23andMe's major shareholders?

23andMe's stock is owned by a variety of retail and institutional investors. Top institutional investors include Mirador Capital Partners LP (0.07%). Insiders that own company stock include Kathy L Hibbs, Kenneth J Hillan and William G Richards. View institutional ownership trends .

How do I buy shares of 23andMe?

Shares of ME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ME

23andMe (ME) Stock Price, News & Analysis

→ Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad)

Free ME Stock Alerts

$0.50

+0.14 (+40.06%)

(As of 12:52 PM ET)

Compare

Today's Range: $0.43
▼
$0.62
50-Day Range: $0.36
▼
$0.81
52-Week Range: $0.35
▼
$2.21

Volume: 52.43 million shs
Average Volume: 7.15 million shs
Market Capitalization: $240.93 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $0.47

Get 23andMe alerts:

23andMe MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 11.8% Downside
$0.47 Price Target
Short Interest: Bearish
11.72% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.02
Based on 19 Articles This Week
Insider Trading: Selling Shares
$88,660 Sold Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.22 out of 5 stars

Medical Sector

864th out of 914 stocks

Pharmaceutical Preparations Industry

397th out of 420 stocks

1.0

Analyst's Opinion

Consensus Rating
23andMe has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
23andMe has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
11.72% of the float of 23andMe has been sold short.
Short Interest Ratio / Days to Cover
23andMe has a short interest ratio ("days to cover") of 4.9.
Change versus previous month
Short interest in 23andMe has recently increased by 6.24%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
23andMe does not currently pay a dividend.
Dividend Growth
23andMe does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ME.

2.2

News and Social Media Coverage

News Sentiment
23andMe has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 19 news articles for 23andMe this week, compared to 7 articles on an average week.
Search Interest
22 people have searched for ME on MarketBeat in the last 30 days. This is an increase of 144% compared to the previous 30 days.
MarketBeat Follows
Only 6 people have added 23andMe to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, 23andMe insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $88,660.00 in company stock.
Percentage Held by Insiders
27.55% of the stock of 23andMe is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 36.10% of the stock of 23andMe is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of 23andMe is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of 23andMe is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
23andMe has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

Click here to get instant access to the guide

About 23andMe Stock (NASDAQ:ME)

23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.

ME Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ME Stock News Headlines

April 6, 2024 | insidertrades.com

23andMe Holding Co. (NASDAQ:ME) Insider Kathy L. Hibbs Sells 38,548 Shares

March 23, 2024 | insidertrades.com

Insider Selling: 23andMe Holding Co. (NASDAQ:ME) Insider Sells 38,548 Shares of Stock

April 18, 2024 | Crypto 101 Media (Ad)

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

April 18, 2024 | proactiveinvestors.com

23andMe CEO reveals take-private plan

April 18, 2024 | investorplace.com

ME Stock Alert: CEO Anne Wojcicki Seeks to Save 23andMe in Take-Private Deal

April 18, 2024 | investopedia.com

23andMe CEO Wojcicki Plans To Take DNA-Testing Firm Private

April 18, 2024 | cnbc.com

23andMe CEO Anne Wojcicki considers taking company private

April 18, 2024 | seekingalpha.com

Wall Street Breakfast Podcast: TikTok Divestment Bill On Potential Fast Track

April 18, 2024 | Crypto 101 Media (Ad)

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

April 18, 2024 | msn.com

23andMe Holding (ME) Price Target Decreased by 13.33% to 1.26

April 18, 2024 | msn.com

23andMe CEO Anne Wojcicki eyes taking DNA-testing company private

April 18, 2024 | finance.yahoo.com

23andMe announces CEO’s intention to pursue a potential take-private

April 18, 2024 | globenewswire.com

23andMe announces CEO's intention to pursue a potential take-private

April 18, 2024 | 247wallst.com

23andMe May Disappear as Public Stock

April 18, 2024 | msn.com

23andMe CEO Anne Wojcicki Plans to Take Company Private

April 17, 2024 | reuters.com

23andMe CEO Wojcicki considering taking firm private, filing shows

April 17, 2024 | finance.yahoo.com

Can 23andMe Holding (NASDAQ:ME) Afford To Invest In Growth?

April 17, 2024 | americanbankingnews.com

23andMe (NASDAQ:ME) Price Target Cut to $0.47 by Analysts at Citigroup

April 15, 2024 | bizjournals.com

23andMe shrinks its South San Francisco headquarters footprint

April 15, 2024 | msn.com

Kim Kardashian, Elon Musk: Breakthrough Prize Red Carpet Photos

April 15, 2024 | msn.com

Robert Downey Jr., Kim Kardashian, Katy Perry and more stars celebrate 10th Breakthrough Prize

April 14, 2024 | msn.com

‘Can I have an Irish passport?’ – US actor Walton Goggins discovers he’s descended from an Irish High King

April 9, 2024 | forbes.com

Outlook On Navigating The Complex Cybersecurity Landscape

April 8, 2024 | msn.com

Unraveling the genetics behind different levels of alcohol consumption

April 7, 2024 | investing.com

23andMe presents cancer therapy data at AACR meeting

April 5, 2024 | globenewswire.com

23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024

April 4, 2024 | forbes.com

Walking Pad Deals: Save Up To $299 On Best-Selling Models

See More Headlines

Receive ME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 23andMe and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/07/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/23/2024
Fiscal Year End: 3/31/2025

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ME
CUSIP: N/A
CIK: 1804591
Web: vgacquisition.com
Phone: 650-938-6300
Fax: N/A
Employees: 769
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $0.47
High Stock Price Target: $0.47
Low Stock Price Target: $0.47
Potential Upside/Downside: -2.1%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.11)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-311,660,000.00
Net Margins: -210.48%
Pretax Margin: -210.71%
Return on Equity: -52.99%
Return on Assets: -39.32%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.15
Quick Ratio: 2.04

Sales & Book Value

Annual Sales: $299.49 million
Price / Sales: 0.77
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.55 per share
Price / Book: 0.31

Miscellaneous

Outstanding Shares: 482,920,000
Free Float: 349,873,000
Market Cap: $231.95 million
Optionable: Not Optionable
Beta: 1.27

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Ms. Anne Wojcicki
Co-Founder, CEO, President & Chair of the Board
Mr. Joseph Selsavage (Age 61)
Interim CFO & Accounting Officer
Comp: $574.56k
Ms. Kathy L. Hibbs Esq. (Age 60)
J.D., Chief Administrative Officer & Corporate Secretary
Comp: $699.8k
Mr. Guy Chayoun
Vice President & Interim General Counsel
Ms. Katie Watson (Age 46)
Vice President of Communications
Mr. Jonathan Ward
Chief Marketing Officer
Mr. Reza Afkhami M.B.A.
Chief Corporate Development Officer
Ms. Savita Pillai
Vice President of People
Dr. Jennifer Low (Age 55)
Head of Therapeutics Development
Mr. Kent Hillyer (Age 56)
Vice President of Consumer Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ME Stock Analysis - Frequently Asked Questions

Should I buy or sell 23andMe stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 23andMe in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ME shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ME, but not buy additional shares or sell existing shares.
View ME analyst ratings or view top-rated stocks.
What is 23andMe's stock price target for 2024?: 1 brokerages have issued 12 month price objectives for 23andMe's shares. Their ME share price targets range from $0.47 to $0.47. On average, they expect the company's share price to reach $0.47 in the next year. This suggests that the stock has a possible downside of 11.8%.
View analysts price targets for ME or view top-rated stocks among Wall Street analysts.
How have ME shares performed in 2024?: 23andMe's stock was trading at $0.9135 on January 1st, 2024. Since then, ME shares have decreased by 41.7% and is now trading at $0.5329.
View the best growth stocks for 2024 here.
When is 23andMe's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 23rd 2024.
View our ME earnings forecast.
How were 23andMe's earnings last quarter?: 23andMe Holding Co. (NASDAQ:ME) posted its quarterly earnings results on Wednesday, February, 7th. The company reported ($0.17) earnings per share (EPS) for the quarter. The business had revenue of $44.75 million for the quarter, compared to the consensus estimate of $56.30 million. 23andMe had a negative net margin of 210.48% and a negative trailing twelve-month return on equity of 52.99%.

What ETF holds 23andMe's stock?: Global X Telemedicine & Digital Health ETF holds 539,538 shares of ME stock, representing 0.81% of its portfolio.
What guidance has 23andMe issued on next quarter's earnings?: 23andMe updated its FY 2024 earnings guidance on Wednesday, February, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $215.0 million-$220.0 million, compared to the consensus revenue estimate of $245.5 million.
Who are 23andMe's major shareholders?: 23andMe's stock is owned by a variety of retail and institutional investors. Top institutional investors include Mirador Capital Partners LP (0.07%). Insiders that own company stock include Kathy L Hibbs, Kenneth J Hillan and William G Richards.
View institutional ownership trends.
How do I buy shares of 23andMe?: Shares of ME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ME) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

23andMe (ME) Stock Price, News & Analysis

23andMe MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About 23andMe Stock (NASDAQ:ME)

ME Stock Price History

ME Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ME Stock Analysis - Frequently Asked Questions

Overall MarketRank^™